vs

Side-by-side financial comparison of MARTIN MIDSTREAM PARTNERS L.P. (MMLP) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $187.7M, roughly 1.1× MARTIN MIDSTREAM PARTNERS L.P.). MARTIN MIDSTREAM PARTNERS L.P. runs the higher net margin — 1.7% vs -62.0%, a 63.7% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs -2.5%). MARTIN MIDSTREAM PARTNERS L.P. produced more free cash flow last quarter ($-6.0M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 0.8%).

Martin Midstream Partners L.P. is a U.S.-based midstream energy services provider. It offers storage, transportation, distribution and processing solutions for crude oil, natural gas liquids, refined petroleum products and specialty chemicals, mainly serving customers across North American energy and industrial segments.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

MMLP vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.1× larger
RARE
$207.3M
$187.7M
MMLP
Growing faster (revenue YoY)
RARE
RARE
+28.4% gap
RARE
25.9%
-2.5%
MMLP
Higher net margin
MMLP
MMLP
63.7% more per $
MMLP
1.7%
-62.0%
RARE
More free cash flow
MMLP
MMLP
$94.7M more FCF
MMLP
$-6.0M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
0.8%
MMLP

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
MMLP
MMLP
RARE
RARE
Revenue
$187.7M
$207.3M
Net Profit
$3.2M
$-128.6M
Gross Margin
Operating Margin
4.1%
-54.7%
Net Margin
1.7%
-62.0%
Revenue YoY
-2.5%
25.9%
Net Profit YoY
-37.1%
3.5%
EPS (diluted)
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MMLP
MMLP
RARE
RARE
Q1 26
$187.7M
Q4 25
$174.2M
$207.3M
Q3 25
$168.7M
$159.9M
Q2 25
$180.7M
$166.5M
Q1 25
$192.5M
$139.3M
Q4 24
$171.3M
$164.6M
Q3 24
$170.9M
$139.5M
Q2 24
$184.5M
$147.0M
Net Profit
MMLP
MMLP
RARE
RARE
Q1 26
$3.2M
Q4 25
$-2.9M
$-128.6M
Q3 25
$-8.4M
$-180.4M
Q2 25
$-2.4M
$-115.0M
Q1 25
$-1.0M
$-151.1M
Q4 24
$-8.9M
$-133.2M
Q3 24
$-3.3M
$-133.5M
Q2 24
$3.8M
$-131.6M
Gross Margin
MMLP
MMLP
RARE
RARE
Q1 26
Q4 25
57.1%
Q3 25
55.1%
Q2 25
56.5%
Q1 25
53.5%
Q4 24
58.2%
Q3 24
58.5%
Q2 24
58.4%
Operating Margin
MMLP
MMLP
RARE
RARE
Q1 26
4.1%
Q4 25
7.3%
-54.7%
Q3 25
4.1%
-106.9%
Q2 25
8.2%
-64.8%
Q1 25
7.5%
-102.6%
Q4 24
4.0%
-74.3%
Q3 24
7.4%
-94.6%
Q2 24
10.8%
-79.1%
Net Margin
MMLP
MMLP
RARE
RARE
Q1 26
1.7%
Q4 25
-1.7%
-62.0%
Q3 25
-5.0%
-112.8%
Q2 25
-1.3%
-69.0%
Q1 25
-0.5%
-108.5%
Q4 24
-5.2%
-80.9%
Q3 24
-1.9%
-95.7%
Q2 24
2.0%
-89.5%
EPS (diluted)
MMLP
MMLP
RARE
RARE
Q1 26
Q4 25
$-1.28
Q3 25
$-1.81
Q2 25
$-1.17
Q1 25
$-1.57
Q4 24
$-1.34
Q3 24
$-1.40
Q2 24
$-1.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MMLP
MMLP
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$-80.0M
Total Assets
$537.1M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MMLP
MMLP
RARE
RARE
Q1 26
Q4 25
$421.0M
Q3 25
$202.5M
Q2 25
$176.3M
Q1 25
$127.1M
Q4 24
$174.0M
Q3 24
$150.6M
Q2 24
$480.7M
Total Debt
MMLP
MMLP
RARE
RARE
Q1 26
Q4 25
$428.0M
Q3 25
$441.3M
Q2 25
$427.8M
Q1 25
$451.4M
Q4 24
$437.6M
Q3 24
$469.3M
Q2 24
$439.4M
Stockholders' Equity
MMLP
MMLP
RARE
RARE
Q1 26
Q4 25
$-80.0M
Q3 25
$9.2M
Q2 25
$151.3M
Q1 25
$144.2M
Q4 24
$255.0M
Q3 24
$346.8M
Q2 24
$432.4M
Total Assets
MMLP
MMLP
RARE
RARE
Q1 26
$537.1M
Q4 25
$522.4M
$1.5B
Q3 25
$510.1M
$1.2B
Q2 25
$515.6M
$1.3B
Q1 25
$533.4M
$1.3B
Q4 24
$538.5M
$1.5B
Q3 24
$554.8M
$1.5B
Q2 24
$535.1M
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MMLP
MMLP
RARE
RARE
Operating Cash FlowLast quarter
$-99.8M
Free Cash FlowOCF − Capex
$-6.0M
$-100.8M
FCF MarginFCF / Revenue
-3.2%
-48.6%
Capex IntensityCapex / Revenue
1.6%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$27.2M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MMLP
MMLP
RARE
RARE
Q1 26
Q4 25
$22.4M
$-99.8M
Q3 25
$-1.2M
$-91.4M
Q2 25
$30.9M
$-108.3M
Q1 25
$-6.0M
$-166.5M
Q4 24
$42.2M
$-79.3M
Q3 24
$-15.8M
$-67.0M
Q2 24
$11.8M
$-77.0M
Free Cash Flow
MMLP
MMLP
RARE
RARE
Q1 26
$-6.0M
Q4 25
$15.6M
$-100.8M
Q3 25
$-7.9M
$-92.7M
Q2 25
$25.6M
$-110.7M
Q1 25
$-11.9M
$-167.8M
Q4 24
$34.2M
$-79.5M
Q3 24
$-25.6M
$-68.6M
Q2 24
$-696.0K
$-79.0M
FCF Margin
MMLP
MMLP
RARE
RARE
Q1 26
-3.2%
Q4 25
8.9%
-48.6%
Q3 25
-4.7%
-58.0%
Q2 25
14.2%
-66.5%
Q1 25
-6.2%
-120.5%
Q4 24
20.0%
-48.3%
Q3 24
-15.0%
-49.2%
Q2 24
-0.4%
-53.7%
Capex Intensity
MMLP
MMLP
RARE
RARE
Q1 26
1.6%
Q4 25
3.9%
0.5%
Q3 25
4.0%
0.8%
Q2 25
3.0%
1.5%
Q1 25
3.1%
1.0%
Q4 24
4.6%
0.1%
Q3 24
5.8%
1.2%
Q2 24
6.8%
1.4%
Cash Conversion
MMLP
MMLP
RARE
RARE
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
3.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MMLP
MMLP

Specialty products$61.6M33%
Transportation *$52.8M28%
Other$46.5M25%
Terminalling and storage *$22.4M12%
Sulfur services$4.4M2%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons